Previous 10 | Next 10 |
April 8, 2020 Palm Beach, FL – April 8, 2020 – The search for vaccines and treatments for the global health crises is now focusing on medicines that are presently approved for other ailments. A recent article in the LA Times discussed this issue saying that when ...
Nano cap Moleculin Biotech (NASDAQ: MBRX ) announces the results of in vitro testing in Germany showing that 2-deoxy-D-glucose (2-DG) totally stopped the replication of the SARS-CoV-2 virus. Specifically, researchers at the University of Frankfurt reported that inhibiting glycolysis (sug...
HOUSTON , April 8, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that independent research found 2-deoxy-D-glucose ("2-DG") to reduce repl...
HOUSTON , April 2, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced it has completed the latest (210 mg/m 2...
NEW YORK, March 30, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced that the presentations from its inaugural conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live company presentations and interactive...
NEW YORK, March 24, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its inaugural event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and...
HOUSTON, March 24, 2020 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that Walter Kl...
VANCOUVER, British Columbia, March 24, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD” ) a clinical stage pharmaceutical company , announces it has entered into a development agreement (the “ Agreement...
Moleculin Biotech (NASDAQ: MBRX ) has filed a new patent application covering the use of WP1122 and its analogs as therapies to limit the ability of coronavirus and other viruses to replicate. More news on: Moleculin Biotech, Inc., Healthcare stocks news, Stocks on the move, Read mor...
HOUSTON , March 20, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that a new patent application has been...
News, Short Squeeze, Breakout and More Instantly...
Moleculin Biotech Inc. Company Name:
MBRX Stock Symbol:
NASDAQ Market:
Moleculin Biotech Inc. Website:
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML PR Newswire HOUSTON , July 10, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfoli...
2024-06-17 10:10:00 ET June 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the compan...
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial PR Newswire – 89% of CRc's were subjects with "poor prognosis" cytogenetics and/or mutations – Current median durability of response (mDOR) of CRc's = 6 months and in...